Voice of Regenerative Medicine : Dr. Xuejun Parsons, the founder of Xcelthera Inc and San Diego Regenerative Medicine Institute, is going to speak at Cell Therapy 2014 Las Vegas on Current State of Regenerative Medicine -- Moving Stem Cell Research from Animals into Humans for Clinical Trials

Friday, October 24, 2014

Dr. Xuejun Parsons, the founder of Xcelthera Inc and San Diego Regenerative Medicine Institute, is going to speak at Cell Therapy 2014 Las Vegas on Current State of Regenerative Medicine -- Moving Stem Cell Research from Animals into Humans for Clinical Trials

Title: Direct Conversion of Pluripotent Human Embryonic Stem Cells into Functional Human Neuronal or Cardiomyocyte Cell Therapy Derivatives for Regenerative Medicine

Abstract: Given the limited capacity of CNS and heart for self-repair/renewal, cell-based therapy represents a promising therapeutic approach closest to provide a cure to restore normal tissue and function for neurological and cardiovascular disorders. Derivation of human embryonic stem cell (hESCs) from the in vitro fertilization (IVF) leftover embryos has brought a new era of cellular medicine for the damaged CNS and heart. Recent advances and technology breakthroughs in hESC research have overcome some major obstacles in moving stem cell research from animals towards humans trials, including resolving minimal essential human requirements for de novo derivation and long-term maintenance of clinically-suitable stable hESC lines and direct conversion of such pluripotent hESCs into a large supply of clinical-grade functional human neuronal or cardiomyocyte cell therapy products. Such breakthrough stem cell technologies have demonstrated the direct pharmacologic utility and capacity of hESC cell therapy derivatives for human CNS and myocardium regeneration and, thus, have presented the hESC cell therapy derivatives as a powerful pharmacologic agent of cellular entity for CNS and heart repair. The availability of human stem/progenitor/precursor cells in high quality and large commercial scales with adequate cellular neurogenic or cardiogenic capacity will greatly facilitate developing safe and effective cell-based regenerative therapies against a wide range of CNS and heart disorders. Transforming non-functional pluripotent hESCs into fate-restricted functional human cell therapy derivatives dramatically increases the clinical efficacy of graft-dependent repair and safety of hESC-derived cellular products, marking a turning point in cell-based regenerative medicine from current studies in animals towards human trials.

Time and Location: Wednesday, October 29, 2014 at Embassy Suites, Las Vegas, 4315 Swenson Street, Las Vegas, Nevada 89119, USA

No comments:

Post a Comment

Public Interest

The successful derivation of human embryonic stem cell (human ES cell) lines from the in vitro fertilization (IVF) leftover embryos is considered as one of the major breakthroughs of the life sciences. The pluripotent human ES cells, derived from the inner cell mass (ICM) or epiblast of human blastocyst or human embryos, have both the unconstrained capacity for long-term stable undifferentiated growth in culture and the intrinsic potential for differentiation into all somatic cell types in the human body, holding tremendous potential for human tissue and function restoration. Therefore, human ES cells have been regarded as an ideal source to provide an unlimited supply of large-scale well-characterized human specialized cell types for cell-based therapies to resolve some worldwide major health problems, such as neurodegenerative diseases, paralysis, diabetes, and heart diseases. A small portion of the millions of excess embryos currently stored in the IVF clinics worldwide, which are otherwise destined for destruction, could potentially be an unlimited source to deliver in the future a whole range of therapeutic treatments for tissue and function restoration in patients with life-threatening diseases and injuries. However, human ES cell research has generated intense public interest as well as controversy due to concerns of products of human ES cell cultures that can only be obtained by the use, involving their destruction, of human embryos. The recent years’ court battles on Federal funding for human ES cell research in the United State (US) as well as the patentability of US and international patents directed to human ES cell technologies have also highlighted the decade long ethical, moral, social, and legal controversy surrounding the public interest of human ES cells involving destruction, commercial or industrial uses of human embryos. As neurodegenerative and heart diseases incur exorbitant costs on the healthcare system worldwide, there is a strong focus on providing newer and more efficient solutions for these therapeutic needs. Millions of people are pinning their hopes on human ES cell research. California voters have passed Proposition 71 to designate $3B public fund to support pluripotent human ES cell research and therapy development for the benefit of public health. In spite of ethical debates surrounding the ownership and funding issues of human ES cells, in the case of many incurable or hitherto untreatable life-threatening or devastating diseases, supporting human ES cell research is crucial to driving the advance of medicine to provide optimal regeneration and reconstruction treatment options to improve the function, wellness, and overall quality of life. To answer the intense public interest surrounding human ES cell research and enormous public healthcare benefits thereof, Voice of Regenerative Medicine provides a ground of public debate or voice or blog for the controversies surrounding public interest of human ES cells centering on scientific, economic, ethical, moral, social, financial conflict of interest, and legal issues, to increase public awareness and understanding of the scientific advancement of human ES cell research, and of the importance, urgency, and tangible benefits of human ES cell-based regenerative medicine to improving the function, wellness, and overall quality of life for patients suffering from incurable or hitherto untreatable life-threatening or devastating diseases; to increase public support for human ES cell research; to improve policy making and funding situation for human ES cell research, and to identify and disclose publicly those scientific, economic, ethical, moral, social, financial conflict of interest, and legal issues that have impeded the progress of human ES cell research and stem cell therapy development, introduction of medical innovations and new business opportunities based on human ES cell research, and bringing new therapeutics into the market.

Disclaimer:

This “Voice of Regenerative Medicine” blog is to provide a public voice and an open forum to human embryonic stem cell research and regenerative medicine start-up. All content provided on this blog is for informational purposes only. This blog makes no representations as to accuracy, completeness, correctness, reliability, suitability, or validity of any information on this site or found by following any link on this site, and will not be liable for any errors or omissions or availability in this information, or any losses, injuries, or damages arising from the display or use of this information. The inclusion of any content, images, documents, files, and links on the blog does not necessarily imply a recommendation or endorse the views expressed within them. The content of any postings or comments on the blog do not necessary reflect or do not necessary represent the positions, strategies, views, or opinions of the owners, authors, bloggers, or San Diego Regenerative Medicine Institute or any organizations or any companies or any director, officer, or employee thereof. This blog is not associated with, affiliated with, a partner with, belonging to, or acting upon any organizations or individuals. The blog’s content is not generated to make money or paid for blogging content. It is natural for the content on the blog to be controversial or contentious. The content on the blog is the opinion only, not intended to malign any religion, ethnic group, club, organization, company, or individual, or anyone or anything. The owners, bloggers, San Diego Regenerative Medicine Institute, any individuals, any organizations, and any companies are not responsible, nor will be held liable, for the content or comments or the display or use of any information on the blog. Our intention is to do no harm, to not injure others, defame, or libel. All information is provided on an as-is basis. These terms and conditions are subject to change at anytime and without notice.